2nd Annual Faces and Cases in Women's Health Conference: Managing Women's Health Issues Across a Lifespan

Dallas, TX
Saturday, November 18, 2017


LEARNING OBJECTIVES
Updates in the Management of Postmenopausal Osteoporosis 
NCC Code 2C (CE 1.3 Rx 1.3)
  • Review the recent updates and recommendations in the osteoporosis treatment guidelines from the ACP, ACE/AACE, and ASBMR/NOF
  • Evaluate the efficacy and safety data for available and emerging pharmacotherapies for osteoporosis
  • Discuss evidence-based best practice guidelines for proper sequencing of therapy based on treat-to-target goals
Current Management Strategies and Updates in Diagnosis and Treatment for Bacterial Vaginosis 
NCC Code 2A (CE 1.3 Rx 1)
  • Identify criteria for diagnosing BV in clinical practice 
  • Evaluate current clinical data for new and emerging therapies for the management of BV and recurrent BV
  • Implement updated treatment and educational strategies for women presenting with recurrent BV
Contraception – No more excuses!
NCC Code 1 (CE 1.3 Rx 0.4)
  • Describe the U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 (U.S. MEC)
  • Identify barriers and develop strategies for consistent and effective contraceptive use
  • Discuss the guidance in specific situations, based on clinical scenarios
Updates in the Diagnosis and Management of HSDD 
NCC Code 2A (CE 1.3 Rx 0.8)
  • Identify communication strategies and screening tools that aid in the identification and diagnosis of HSDD
  • Consider differential diagnoses of low sexual desire before initiating targeted treatment for HSDD
  • Evaluate efficacy and safety data for approved, emerging, and off-label treatments for HSDD

ACTIVITY NUMBER: 17-11

CE APPROVAL HOURS

5.5 Contact Hours of CE Credit, including 3.5 Contact Hours of Pharmacology Content

ACCREDITATION

This live activity, Managing Women’s Health Issues Across a Lifespan, on November 18, 2017, has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health for 5.5 contact hours of continuing education, including 3.5 contact hours of pharmacology content. Each participant should claim only those contact hours that he/she actually spent in the educational activity.

DISCLOSURE OF UNLABELED USE

NPWH policy requires authors to disclose to participants when presenting information about unlabeled use of a commercial product or device or an individual use of a drug or device not yet approved for any use.

THERAPEUTIC DISCLAIMER

Participating faculty members determine the editorial content of CE activities; this content does not necessarily represent the views of NPWH. This content has undergone a blinded peer review process for validation of clinical content. Although every effort has been made to ensure that the information is accurate, clinicians are responsible for evaluating this information in relation to generally accepted standards in their own communities and integrating the information in this activity with that of established recommendations of other authorities, national guidelines, FDA approved package inserts, and individual patient characteristics.